264 related articles for article (PubMed ID: 29079337)
1. Oseltamivir-zanamivir combination therapy suppresses drug-resistant H1N1 influenza A viruses in the hollow fiber infection model (HFIM) system.
Pires de Mello CP; Drusano GL; Adams JR; Shudt M; Kulawy R; Brown AN
Eur J Pharm Sci; 2018 Jan; 111():443-449. PubMed ID: 29079337
[TBL] [Abstract][Full Text] [Related]
2. Zanamivir, at 600 milligrams twice daily, inhibits oseltamivir-resistant 2009 pandemic H1N1 influenza virus in an in vitro hollow-fiber infection model system.
Brown AN; McSharry JJ; Weng Q; Adams JR; Kulawy R; Drusano GL
Antimicrob Agents Chemother; 2011 Apr; 55(4):1740-6. PubMed ID: 21263046
[TBL] [Abstract][Full Text] [Related]
3. Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A(H1N1) viruses.
Okomo-Adhiambo M; Nguyen HT; Sleeman K; Sheu TG; Deyde VM; Garten RJ; Xu X; Shaw MW; Klimov AI; Gubareva LV
Antiviral Res; 2010 Feb; 85(2):381-8. PubMed ID: 19917319
[TBL] [Abstract][Full Text] [Related]
4. Influenza A(H1N1)pdm09 resistance and cross-decreased susceptibility to oseltamivir and zanamivir antiviral drugs.
Correia V; Santos LA; Gíria M; Almeida-Santos MM; Rebelo-de-Andrade H
J Med Virol; 2015 Jan; 87(1):45-56. PubMed ID: 25042157
[TBL] [Abstract][Full Text] [Related]
5. Synergistic effect of nitazoxanide with neuraminidase inhibitors against influenza A viruses in vitro.
Belardo G; Cenciarelli O; La Frazia S; Rossignol JF; Santoro MG
Antimicrob Agents Chemother; 2015 Feb; 59(2):1061-9. PubMed ID: 25451059
[TBL] [Abstract][Full Text] [Related]
6. Oseltamivir-zanamivir bitherapy compared to oseltamivir monotherapy in the treatment of pandemic 2009 influenza A(H1N1) virus infections.
Escuret V; Cornu C; Boutitie F; Enouf V; Mosnier A; Bouscambert-Duchamp M; Gaillard S; Duval X; Blanchon T; Leport C; Gueyffier F; Van Der Werf S; Lina B
Antiviral Res; 2012 Nov; 96(2):130-7. PubMed ID: 22909899
[TBL] [Abstract][Full Text] [Related]
7. Influenza virus resistance to neuraminidase inhibitors.
Samson M; Pizzorno A; Abed Y; Boivin G
Antiviral Res; 2013 May; 98(2):174-85. PubMed ID: 23523943
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro.
Gubareva LV; Trujillo AA; Okomo-Adhiambo M; Mishin VP; Deyde VM; Sleeman K; Nguyen HT; Sheu TG; Garten RJ; Shaw MW; Fry AM; Klimov AI
Antivir Ther; 2010; 15(8):1151-9. PubMed ID: 21149922
[TBL] [Abstract][Full Text] [Related]
9. Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa.
Hurt AC; Ernest J; Deng YM; Iannello P; Besselaar TG; Birch C; Buchy P; Chittaganpitch M; Chiu SC; Dwyer D; Guigon A; Harrower B; Kei IP; Kok T; Lin C; McPhie K; Mohd A; Olveda R; Panayotou T; Rawlinson W; Scott L; Smith D; D'Souza H; Komadina N; Shaw R; Kelso A; Barr IG
Antiviral Res; 2009 Jul; 83(1):90-3. PubMed ID: 19501261
[TBL] [Abstract][Full Text] [Related]
10. Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro.
Nguyen JT; Hoopes JD; Le MH; Smee DF; Patick AK; Faix DJ; Blair PJ; de Jong MD; Prichard MN; Went GT
PLoS One; 2010 Feb; 5(2):e9332. PubMed ID: 20179772
[TBL] [Abstract][Full Text] [Related]
11. Antiviral drug susceptibilities of seasonal human influenza viruses in Lebanon, 2008-09 season.
Zaraket H; Saito R; Wakim R; Tabet C; Medlej F; Reda M; Baranovich T; Suzuki Y; Dapat C; Caperig-Dapat I; Dbaibo GS; Suzuki H
J Med Virol; 2010 Jul; 82(7):1224-8. PubMed ID: 20513088
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of favipiravir and neuraminidase inhibitor combinations against oseltamivir-sensitive and oseltamivir-resistant pandemic influenza A (H1N1) virus.
Tarbet EB; Vollmer AH; Hurst BL; Barnard DL; Furuta Y; Smee DF
Arch Virol; 2014 Jun; 159(6):1279-91. PubMed ID: 24311151
[TBL] [Abstract][Full Text] [Related]
13. A zanamivir dimer with prophylactic and enhanced therapeutic activity against influenza viruses.
Tarbet EB; Hamilton S; Vollmer AH; Luttick A; Ng WC; Pryor M; Hurst BL; Crawford S; Smee DF; Tucker SP
J Antimicrob Chemother; 2014 Aug; 69(8):2164-74. PubMed ID: 24777908
[TBL] [Abstract][Full Text] [Related]
14. A two-year survey of the oseltamivir-resistant influenza A(H1N1) virus in Yamagata, Japan and the clinical effectiveness of oseltamivir and zanamivir.
Matsuzaki Y; Mizuta K; Aoki Y; Suto A; Abiko C; Sanjoh K; Sugawara K; Takashita E; Itagaki T; Katsushima Y; Ujike M; Obuchi M; Odagiri T; Tashiro M
Virol J; 2010 Mar; 7():53. PubMed ID: 20202225
[TBL] [Abstract][Full Text] [Related]
15. In vitro passaging of a pandemic H1N1/09 virus selects for viruses with neuraminidase mutations conferring high-level resistance to oseltamivir and peramivir, but not to zanamivir.
McKimm-Breschkin JL; Rootes C; Mohr PG; Barrett S; Streltsov VA
J Antimicrob Chemother; 2012 Aug; 67(8):1874-83. PubMed ID: 22563014
[TBL] [Abstract][Full Text] [Related]
16. Resistance to Mutant Group 2 Influenza Virus Neuraminidases of an Oseltamivir-Zanamivir Hybrid Inhibitor.
Wu Y; Gao F; Qi J; Bi Y; Fu L; Mohan S; Chen Y; Li X; Pinto BM; Vavricka CJ; Tien P; Gao GF
J Virol; 2016 Dec; 90(23):10693-10700. PubMed ID: 27654293
[TBL] [Abstract][Full Text] [Related]
17. Genotypic and phenotypic resistance of pandemic A/H1N1 influenza viruses circulating in Germany.
Duwe SC; Wedde M; Birkner P; Schweiger B
Antiviral Res; 2011 Jan; 89(1):115-8. PubMed ID: 21070812
[TBL] [Abstract][Full Text] [Related]
18. Detection of human influenza A (H1N1) and B strains with reduced sensitivity to neuraminidase inhibitors.
Escuret V; Frobert E; Bouscambert-Duchamp M; Sabatier M; Grog I; Valette M; Lina B; Morfin F; Ferraris O
J Clin Virol; 2008 Jan; 41(1):25-8. PubMed ID: 18055253
[TBL] [Abstract][Full Text] [Related]
19. Development of oseltamivir and zanamivir resistance in influenza A(H1N1)pdm09 virus, Denmark, 2014.
Trebbien R; Pedersen SS; Vorborg K; Franck KT; Fischer TK
Euro Surveill; 2017 Jan; 22(3):. PubMed ID: 28128091
[TBL] [Abstract][Full Text] [Related]
20. Characterization of drug-resistant recombinant influenza A/H1N1 viruses selected in vitro with peramivir and zanamivir.
Baz M; Abed Y; Boivin G
Antiviral Res; 2007 May; 74(2):159-62. PubMed ID: 17137644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
